Market Place
Sourcing Support
CSL`s Garadacimab Approved By CHMP For Hereditary Angioedema
13 Dec 2024 //
PR NEWSWIRE
CSL Behring shuts down California cell and gene therapy R&D site
19 Nov 2024 //
FIERCE BIOTECH
CSL Behring Treats First European Patients With HEMGENIX Gene Therapy
04 Jul 2024 //
GLOBENEWSWIRE
UniQure, with sale of plant, outsources Hemgenix manufacturing
02 Jul 2024 //
BIOPHARMADIVE
CSL Behring cuts headcount by 65 at Illinois plant
15 Apr 2024 //
FIERCE PHARMA
Midas Team Readies For Pharma-Cup 2024 Soccer Challenge
20 Mar 2024 //
PRESS RELEASE
Kyowa`s Orchard hopes $4.25M gene therapy price tag bears fruit
20 Mar 2024 //
FIERCE PHARMA
CSL and uniQure unveil three-year data for one-time hemophilia B gene therapy
09 Feb 2024 //
ENDPTS
CSL Behring Announces Availability of Hizentra 10g Prefilled Syringe
03 Jan 2024 //
PR NEWSWIRE
CSL Behring Demonstrates Continued Commitment to Alpha-1 Community
02 Jan 2024 //
PR NEWSWIRE
FDA, EMA accept Pfizer`s hemophilia B gene therapy
27 Jun 2023 //
ENDPTS
CSL doses first patient with haemophilia B gene therapy Hemgenix
21 Jun 2023 //
PHARMACEUTICAL TECHNOLOGY
CSL`s Hemgenix (Etranacogene Dezaparvovec) Receives Approval in Europe
20 Jun 2023 //
EMA
CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX
20 Jun 2023 //
PR NEWSWIRE
CSL Behring Receives FDA Approval for Hizentra®
18 Apr 2023 //
PR NEWSWIRE
New CEO Paul McKenzie plots CSL`s course for growth
03 Apr 2023 //
FIERCE PHARMA
CSL`s Hemgenix (etranacogene dezaparvovec) Approved In Europe
28 Feb 2023 //
EMA
Orsini Specialty Pharmacy Selected by CSL Behring as a Limited Distribution
20 Dec 2022 //
PR NEWSWIRE
CSL`s hemophilia B gene therapy works well through 24 months
12 Dec 2022 //
FIERCEPHARMA
American Lung Association taps CSL Seqirus for flu vax campaign
06 Dec 2022 //
FIERCEPHARMA
Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix
02 Dec 2022 //
FORBES
Australia`s CSL prices hemophilia gene therapy at $3.5 million
22 Nov 2022 //
REUTERS
BrightInsight Inks Enterprise Agreement with CSL Behring
14 Nov 2022 //
GLOBENEWSWIRE
Can gene therapies for haemophilia defend their high price tags?
09 Nov 2022 //
PHARMACEUTICAL-TECHNOLOGY
ICER Publishes Evidence Report on Gene Therapies for Hemophilia A and B
03 Nov 2022 //
ICER
ICER says it`s fair for BioMarin &CSL toprice incoming hemophilia gene therapies
02 Nov 2022 //
ENDPTS
CSL Receives Manufacturing & MKT Authorization in Japan for “Berinert S.C. Inj
27 Sep 2022 //
MARKETSCREENER
CSL Behring teams with famous photographer to focus on hemophilia for campaign
11 Jun 2022 //
ENDPTS
CSL-UniQure Hemophilia B Gene Therapy Scores Priority Review
25 May 2022 //
BIOSPACE
Publication of definitive end result for Vifor Pharma tender offer
28 Mar 2022 //
BUSINESSWIRE
CSL and Grifols sue US border patrol for blocking Mexican plasma donations
11 Mar 2022 //
ENDPTS
Result for Vifor Pharma tender offer: CSL Behring declares offer successful
07 Mar 2022 //
BUSINESSWIRE
Publication of provisional interim result for Vifor Pharma tender offer
02 Mar 2022 //
BUSINESSWIRE
Pivotal HOPE-B Study Shows Therapeutic Effect of EtranaDez Gene Therapy
04 Feb 2022 //
PRNEWSWIRE
CSL publishes Offer Prospectus on public tender offer for all shares of Vifor
18 Jan 2022 //
BUSINESSWIRE
EMA Grants Accelerated Assessment for CSL Behring`s Haemophilia B Gene Therapy
15 Dec 2021 //
PRNEWSWIRE
CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec
15 Dec 2021 //
PRNEWSWIRE
uniQure & CSL Behring Announce Primary Endpoint Achieved in HOPE-B
09 Dec 2021 //
GLOBENEWSWIRE
UniQure, CSL Behring dash to the FDA with a potential blockbuster gene therapy
09 Dec 2021 //
ENDPTS
US FDA approves CSL Behring’s new Berinert administration kit
04 Aug 2021 //
PHARMABIZ
With CSL all-in on AZ`s shot, Novavax hunts for Aussie partner
22 May 2021 //
FIERCE PHARMA
CSL closes deal for UniQure gene therapy in hopeful sign for M&A
07 May 2021 //
BIOPHARMADIVE
CSL Behring Announces Closing of Global Commercialization and License Agreement
06 May 2021 //
PRNEWSWIRE
Research institute taps into RWE to assess angioedema therapies
14 Apr 2021 //
OUTSURCING-PHARMA
Plasma therapy backed by CSL, Takeda fails phase 3 COVID-19 test
06 Apr 2021 //
FIERCE BIOTECH
UniQure/CSL hem B gene therapy curbs bleeding in phase 3
08 Dec 2020 //
FIERCE BIOTECH
CSL Behring and uniQure’s hemophilia B gene therapy hit its primary endpoint
20 Nov 2020 //
FIERCEBIOTECH
Pharvaris lands another $80M as it looks to tackle Takeda and CSL
18 Nov 2020 //
ENDPTS
Urban League, CSL Behring Partner to Address Community Needs Public Health
16 Nov 2020 //
PRNEWSWIRE
Australian COVID-19 vaccine candidate produces antibody response in early tests
13 Nov 2020 //
REUTERS
CSL Behring To Present New Real-World Data on Outcomes Acute Coronary Syndrome
10 Nov 2020 //
PRNEWSWIRE
CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I
05 Nov 2020 //
PRNEWSWIRE
Orphan Drug Granted for CSL Behring`s Investigational Plasma-Derived Hemopexin
02 Nov 2020 //
PRNEWSWIRE
Australia signs deal with AstraZeneca for possible COVID-19 vaccine
19 Aug 2020 //
REUTERS
CSL Behring evaluates monoclonal Ab for respiratory distress
08 Jul 2020 //
BIOSPECTRUMASIA
CSL Behring evaluates monoclonal antibody in Covid-19 patients
07 Jul 2020 //
CLINICALTRIALSARENA
CSL Behring in $450m spend on hemophilia gene therapy
30 Jun 2020 //
BIOPHARMA-REPORTER
CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy for Hemophilia B
24 Jun 2020 //
CSLBEHRING
CSL Behring Presents Results for Garadacimab as Preventive Treatment
07 Jun 2020 //
PRNEWSWIRE
